Idose Tr Implant
NDC Package 25357-100-99
Package Information
Idose Tr (travoprost intracameral) implants is travoprost is used to treat high pressure inside the eye due to glaucoma (open-angle type) or other eye diseases (e.g., ocular hypertension). This formulation utilizes a implant delivery system. Marketed by Glaukos Corporation, this product is identified by NDC 25357-100 and is authorized under FDA application NDA218010.
Identification & Billing
- RxCUI: 2672088 - travoprost 75 MCG Drug Implant
- RxCUI: 2672088 - travoprost 0.075 MG Drug Implant
- RxCUI: 2672093 - iDose TR 75 MCG Drug Implant
- RxCUI: 2672093 - travoprost 0.075 MG Drug Implant [iDose]
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 25357 - Glaukos Corporation
- 25357-100 - Idose Tr
- 25357-100-99 - 1 POUCH in 1 CARTON / 1 TRAY in 1 POUCH / 1 CANISTER in 1 TRAY / 1 IMPLANT in 1 CANISTER
- 25357-100 - Idose Tr
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (25357-100). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 25357-100-99 identifies a specific commercial package of 1 pouch in 1 carton / 1 tray in 1 pouch / 1 canister in 1 tray / 1 implant in 1 canister of Idose Tr, a human prescription drug labeled by Glaukos Corporation. This implant is formulated for intracameral use and contains travoprost as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Glaukos Corporation on December 13, 2023. The current certification is valid through December 31, 2027.
What are the primary indications for this medication?
Travoprost is used to treat high pressure inside the eye due to glaucoma (open-angle type) or other eye diseases (e.g., ocular hypertension). Lowering high pressure inside the eye can help prevent blindness. This medication works by regulating the flow of fluid within the eye to maintain a normal pressure.
How is this Glaukos Corporation product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 25357010099. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.